YOU ARE HERE:
New drugs news
page  of 16
 
Headline
Date
  South Africa: Delayed drug registrations hard to swallow
09.03.10
  CCR5 antagonist vicriviroc fails to surpass potent background regimen
18.02.10
  New CCR5 antagonist TBR-652 shows good antiviral activity in early study
18.02.10
  Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir
18.02.10
  Tesamorelin safe and effective for fat accumulation in patients taking HIV treatment
03.02.10
  New heat-stable ritonavir tablet approved in Europe
03.02.10
  Merck will not seek vicriviroc licenses in treatment-experienced
21.01.10
  New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
03.11.09
  FDA committee recommends approval of maraviroc for first-line treatment in US
09.10.09
  Maturation inhibitor bevirimat is well tolerated and effective in predicted responders
18.09.09
  Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
18.09.09
  Nutritional formula linked to reduced CD4 cell loss in untreated people
17.09.09
  GSK's second integrase inhibitor looks potent and well-tolerated in early study
17.09.09
  IL-7 may boost CD4 and CD8 T-cells, study shows
17.09.09
  Raltegravir moves closer to approval for first-line use in Europe
27.07.09
  Experimental integrase inhibitor GSK-572 looks good in early studies
22.07.09
  Once-daily Kaletra as safe and effective as twice-daily dosing
22.07.09
  TB Alliance, Tibotec, form partnership to take forward new drug
17.06.09
  New hepatitis C drug may halve the length of treatment, but ribavirin still needed
12.06.09
  New drug for MDR-TB does well in trial
09.06.09

page  of 16